Patents Assigned to AstraZeneca AB
  • Amido heteroaromatic compounds
    Patent number: 12291524
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of diseases such as liver disease.
    Type: Grant
    Filed: September 13, 2024
    Date of Patent: May 6, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Daniel Tor Pettersen, Stéphanie Marcelle Gueret, Nidhal Selmi, Erik Lars Malmerberg, Tord Bertil Inghardt, Jan Åke Lindberg, Jens Peter Brandt, Jon Paul Janet, Björn Erik Anton Holm
  • Methods of delaying pain progression and treating prostate cancer
    Patent number: 12280049
    Abstract: This disclosure relates to methods for delaying pain progression in a subject receiving treatment for prostate cancer. This disclosure further relates to methods for treating prostate cancer, such as for example, treating prostate cancer in a subject having pain.
    Type: Grant
    Filed: August 3, 2021
    Date of Patent: April 22, 2025
    Assignee: ASTRAZENECA AB
    Inventor: Jinyu Kang
  • Methods of treating chronic kidney disease with dapagliflozin
    Patent number: 12274707
    Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
    Type: Grant
    Filed: April 1, 2021
    Date of Patent: April 15, 2025
    Assignee: AstraZeneca AB
    Inventor: Anna Maria Langkilde
  • PHARMACEUTICAL COMPOSITIONS COMPRISING (2S)-N-{(1S)-1-CYANO-2-[4-(3-METHYL-2-OXO-2,3-DIHYDRO-1,3-BENZOXAZOL-5-yl)PHENYL]ETHYL}-1,4- OXAZEPANE-2-CARBOXAMIDE
    Publication number: 20250108060
    Abstract: The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: December 9, 2024
    Publication date: April 3, 2025
    Applicant: ASTRAZENECA AB
    Inventors: Håkan WIKSTRÖM, Jufang Wu LUDVIGSSON, Thomas ANDERSSON
  • Compositions and methods of treating cancer with chimeric antigen receptors
    Patent number: 12264190
    Abstract: This disclosure relates to compositions and methods for treating cancer using armored chimeric antigen receptor cells.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: April 1, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Gordon Moody, Maria Letizia Giardino Torchia, Michael Glen Overstreet, Ryan Gilbreth
  • Protein kinase B inhibitors
    Patent number: 12252495
    Abstract: The invention relates to a novel group of compounds of Formula (I) or salts thereof: wherein Y, Z1, Z2, R1, R4, R5 and n are as described in the specification, which may be useful in the treatment or prevention of a disease or medical condition mediated through protein kinase B (PKB) such as cancer. The invention also relates to pharmaceutical compositions comprising said compounds, methods of treatment of diseases mediated by PKB using said compounds and methods for preparing compounds of Formula (I).
    Type: Grant
    Filed: August 4, 2023
    Date of Patent: March 18, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Paul David Johnson, Andrew Leach, Richard William Arthur Luke, Zbigniew Stanley Matusiak, Jeffrey James Morris
  • IRAK4 inhibitors
    Patent number: 12240832
    Abstract: The present application relates to chemical compounds of Formula (I), and pharmaceutically acceptable salts thereof, that inhibit IRAK4 and consequently have potential utility in medicine.
    Type: Grant
    Filed: March 21, 2024
    Date of Patent: March 4, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Ina Terstiege, Stefan Schiesser
  • Pharmaceutical composition
    Patent number: 12220403
    Abstract: The invention concerns pharmaceutical compositions containing a hydrogen sulphate salt of 6-(4-bromo-2-chloro-phenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxy-ethoxy)-amide and solvates, crystalline forms and amorphous forms thereof, to the use of said compositions as a medicament; and to processes for the preparation of said compositions.
    Type: Grant
    Filed: October 10, 2023
    Date of Patent: February 11, 2025
    Assignees: AstraZeneca AB, Array BioPharma, Inc.
    Inventors: Nicola Frances Bateman, Paul Richard Gellert, Kathryn Jane Hill
  • Methods of treating chronic kidney disease with dapagliflozin
    Patent number: 12213988
    Abstract: The present disclosure is directed to methods of treating patients with chronic kidney disease (CKD), with and without Type 2 diabetes, with an SGLT2 inhibitor, such as dapagliflozin.
    Type: Grant
    Filed: June 14, 2021
    Date of Patent: February 4, 2025
    Assignee: AstraZeneca AB
    Inventor: Anna Maria Langkilde
  • Pharmaceutical compositions comprising (2S)-n-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide
    Patent number: 12201638
    Abstract: The present disclosure relates to pharmaceutical compositions suitable for oral administration, and more particularly to pharmaceutical compositions, including pharmaceutical tablet compositions, containing (2S)-N-{(1S)-1-cyano-2-[4-(3-methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-5-yl)phenyl]ethyl}-1,4-oxazepane-2-carboxamide (Compound A) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 28, 2024
    Date of Patent: January 21, 2025
    Assignee: ASTRAZENECA AB
    Inventors: Håkan Wikström, Jufang Wu Ludvigsson, Thomas Andersson
  • Arginase inhibitors and methods of use thereof
    Patent number: 12195485
    Abstract: Disclosed are compounds of formula (Ia) or a pharmaceutically acceptable salt thereof pharmaceutical compositions comprising compounds of formula (Ia) and methods of using the same for treating cancer or a respiratory inflammatory disease and inhibiting arginase: wherein R1 is —NHR1a; R1a is —H or —C(O)CH(R1b)NHR1c; and R1b is selected from —H, —(C1-C4) alkyl and CH2OR1d and R1c is —H; or R1b and R1c, together with the atom to which they are attached, form a 5-membered heterocyclic ring; and R1d is H or —CH3.
    Type: Grant
    Filed: July 15, 2022
    Date of Patent: January 14, 2025
    Assignee: AstraZeneca AB
    Inventors: Scott Nathan Mlynarski, Tyler Grebe, Sameer Kawatkar, Maurice Raymond Verschoyle Finlay, Iain Simpson, Jianyan Wang, Steve Cook, Dedong Wu
  • Conjugates comprising cleavable linkers
    Patent number: 12178876
    Abstract: The specification relates to conjugates comprising a linker of Formula (ICA): and pharmaceutically acceptable salts thereof. The specification also relates the use of the conjugates for the treatment of diseases such as cancer, and intermediates useful for the synthesis of the conjugates.
    Type: Grant
    Filed: April 9, 2024
    Date of Patent: December 31, 2024
    Assignee: AstraZeneca, AB
    Inventors: Akbar Husain Khan, Andreas Lothar Severino Maderna, Maximillian Taro William Lee, Nicole Danielle Bartolo, William Robert Fraser Goundry
  • Modulators of APOL1 expression
    Patent number: 12168766
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting APOL1 expression, which may be useful for treating, preventing, or ameliorating a disease associated with APOL1.
    Type: Grant
    Filed: November 8, 2022
    Date of Patent: December 17, 2024
    Assignee: ASTRAZENECA AB
    Inventor: Susan M. Freier
  • Method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine and polymorphic forms thereof
    Patent number: 12134613
    Abstract: This specification generally relates to an improved method for the manufacture of 3-[(1S)-1-imidazo[1,2-a]pyridin-6-ylethyl]-5-(1-methylpyrazol-4-yl)triazolo[4,5-b]pyrazine (I), or pharmaceutically acceptable salts thereof; polymorphic forms thereof, and intermediates useful in the manufacture of such compounds and salts thereof.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: November 5, 2024
    Assignees: AstraZeneca AB, Hutchison Medipharma Limited
    Inventors: Andrew Roy Turner, Andrew Timothy Turner, Gareth Paul Howell, Malcolm Allan Young Gall, Keith Raymond Mulholland, Neil Keith Adlington, Zhenping Tian, Bo Liu, Qisun Gong, Wei Yu
  • Combination of zibotentan and dapagliflozin for the treatment of endothelin related diseases
    Patent number: 12121517
    Abstract: The present disclosure relates to the endothelin receptor antagonist (ERA) zibotentan in combination with the sodium-dependent glucose cotransporter 2 (SGLT-2) inhibitor dapagliflozin for use in the treatment of certain endothelin related diseases.
    Type: Grant
    Filed: June 23, 2023
    Date of Patent: October 22, 2024
    Assignee: ASTRAZENECA AB
    Inventors: Peter Greasley, Christine Ahlström, Stanko Skrtic, Robert Menzies, Anne-Kristina Mercier, Mikael Sunnåker
  • Dendrimer formulations
    Patent number: 12115174
    Abstract: Disclosed are pharmaceutical compositions comprising a lyophilized compound of formula (I): (I) or a pharmaceutically acceptable salt thereof, and methods of using the same for treating cancer.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: October 15, 2024
    Assignee: AstraZeneca AB
    Inventors: Paul Gellert, Kathryn Hill, Richard Storey
  • GLP-1 receptor ligand moiety conjugated oligonucleotides and uses thereof
    Patent number: 12115225
    Abstract: The present embodiments provide compounds and methods for targeting cells expressing GLP-1 receptor.
    Type: Grant
    Filed: April 15, 2021
    Date of Patent: October 15, 2024
    Assignees: ASTRAZENECA AB, IONIS PHARMACEUTICALS, INC.
    Inventors: Brett P. Monia, Thazha P. Prakash, Garth A. Kinberger, Richard Lee, Punit P. Seth, Shalini Andersson, Eva Carina Ämmälä, Daniel Laurent Knerr, Maria Astrid Ölwegård-Halvarsson, Eric Valeur, William John Drury, III
  • PYRAZOLE DERIVATIVES USEFUL AS 5-LIPOXYGENASE ACTIVATING PROTEIN (FLAP) INHIBITORS
    Publication number: 20240317767
    Abstract: The present application relates to novel compounds of formula (I) to their utility in treating and/or preventing clinical conditions including cardiovascular diseases (CVD), to methods for their therapeutic use, to pharmaceutical compositions containing them and to processes for preparing such compounds.
    Type: Application
    Filed: May 21, 2024
    Publication date: September 26, 2024
    Applicant: ASTRAZENECA AB
    Inventors: Johan Olof BRODDEFALK, Hans Fredrik EMTENÂS, Kenneth Lars GRANBERG, Malin Anita LEMURELL, Daniel Tor PETTERSEN, Alleyn Thomas PLOWRIGHT, Lars Johan Andreas ULANDER
  • Halo-substituted piperidines as orexin receptor modulators
    Patent number: 12084437
    Abstract: The present application relates to certain halo-substituted piperidine compounds, pharmaceutical compositions containing them, and methods of using them, including methods for treating substance addiction, panic disorder, anxiety, post-traumatic stress disorder, pain, depression, seasonal affective disorder, an eating disorder, or hypertension.
    Type: Grant
    Filed: July 20, 2022
    Date of Patent: September 10, 2024
    Assignees: ASTRAZENECA AB, EOLAS THERAPEUTICS, INC
    Inventors: Theodore M. Kamenecka, Jörg Holenz, Steven Wesolowski, Yuanjun He, Roland Bürli
  • Chemical compounds
    Patent number: 12077530
    Abstract: The specification relates to compounds of Formula (I): and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the treatment of cell proliferative disorders.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: September 3, 2024
    Assignee: ASTRAZENECA AB
    Inventors: Bernard Christophe Barlaam, Daniel Hillebrand O'Donovan, Samantha Jayne Hughes, Thomas Andrew Moss, Johannes Wilhelmus Maria Nissink, James Stewart Scott, Bin Yang